following a full submission:
dostarlimab (Jemperli®) is accepted for use within NHSScotland.
Indication under review: in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
In a double-blind, randomised, phase III study, progression-free survival was significantly improved with dostarlimab in combination with platinum-containing chemotherapy compared with platinum-containing chemotherapy alone in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- dostarlimab (Jemperli)
- SMC ID:
- SMC2635
- Indication:
In combination with platinum-containing chemotherapy (PCC) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 April 2024